Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression
详细信息 查看全文
- 作者：Paromita Raha ; Scott Thomas ; K Ted Thurn ; Jeenah Park…
- 刊名：Breast Cancer Research
- 出版年：2015
- 出版时间：December 2015
- 年：2015
- 卷：17
- 期：1
- 全文大小：1,765 KB
- 参考文献：1. Raha, P, Thomas, S, Munster, PN (2011) Epigenetic modulation: a novel therapeutic target for overcoming hormonal therapy resistance. Epigenomics. 3: pp. 451-470 ss="external" href="http://dx.doi.org/10.2217/epi.11.72" target="_blank" title="It opens in new window">CrossRef
2. Osborne, CK, Schiff, R (2011) Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 62: pp. 233-247 ss="external" href="http://dx.doi.org/10.1146/annurev-med-070909-182917" target="_blank" title="It opens in new window">CrossRef
3. Miller, TW, Balko, JM, Ghazoui, Z, Dunbier, A, Anderson, H, Dowsett, M (2011) A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance. Clin Cancer Res. 17: pp. 2024-2034 ss="external" href="http://dx.doi.org/10.1158/1078-0432.CCR-10-2567" target="_blank" title="It opens in new window">CrossRef
4. Pathiraja, TN, Stearns, V, Oesterreich, S (2010) Epigenetic regulation in estrogen receptor positive breast cancer–role in treatment response. J Mammary Gland Biol Neoplasia. 15: pp. 35-47 ss="external" href="http://dx.doi.org/10.1007/s10911-010-9166-0" target="_blank" title="It opens in new window">CrossRef
5. Kurebayashi, J (2003) Endocrine-resistant breast cancer: underlying mechanisms and strategies for overcoming resistance. Breast Cancer. 10: pp. 112-119 ss="external" href="http://dx.doi.org/10.1007/BF02967635" target="_blank" title="It opens in new window">CrossRef
6. West, AC, Johnstone, RW (2014) New and emerging HDAC inhibitors for cancer treatment. J Clin Invest. 124: pp. 30-39 ss="external" href="http://dx.doi.org/10.1172/JCI69738" target="_blank" title="It opens in new window">CrossRef
7. Thurn, KT, Thomas, S, Moore, A, Munster, PN (2011) Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncol. 7: pp. 263-283 ss="external" href="http://dx.doi.org/10.2217/fon.11.2" target="_blank" title="It opens in new window">CrossRef
8. Hirokawa, Y, Arnold, M, Nakajima, H, Zalcberg, J, Maruta, H (2005) Signal therapy of breast cancers by the HDAC inhibitor FK228 that blocks the activation of PAK1 and abrogates the tamoxifen-resistance. Cancer Biol Ther. 4: pp. 956-960 ss="external" href="http://dx.doi.org/10.4161/cbt.4.9.1911" target="_blank" title="It opens in new window">CrossRef
9. Jang, ER, Lim, SJ, Lee, ES, Jeong, G, Kim, TY, Bang, YJ (2004) The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen. Oncogene. 23: pp. 1724-1736 ss="external" href="http://dx.doi.org/10.1038/sj.onc.1207315" target="_blank" title="It opens in new window">CrossRef
10. Matthews, GM, Newbold, A, Johnstone, RW (2012) Intrinsic and extrinsic apoptotic pathway signaling as determinants of histone deacetylase inhibitor antitumor activity. Adv Cancer Res. 116: pp. 165-197 ss="external" href="http://dx.doi.org/10.1016/B978-0-12-394387-3.00005-7" target="_blank" title="It opens in new window">CrossRef
11. Munster, PN, Thurn, KT, Thomas, S, Raha, P, Lacevic, M, Miller, A (2011) A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer. 104: pp. 1828-1835 ss="external" href="http://dx.doi.org/10.1038/bjc.2011.156" target="_blank" title="It opens in new window">CrossRef
12. Yardley, DA, Ismail-Khan, RR, Melichar, B, Lichinitser, M, Munster, PN, Klein, PM (2013) Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J Clin Oncol. 31: pp. 2128-2135 ss="external" href="http://dx.doi.org/10.1200/JCO.2012.43.7251" target="_blank" title="It opens in new window">CrossRef
13. Thomas, S, Thurn, KT, Raha, P, Chen, S, Munster, PN (2013) Efficacy of histone deacetylase and estrogen receptor inhibition in breast cancer cells due to concerted down regulation of Akt. PLoS One. 8: pp. e68973 ss="external" href="http://dx.doi.org/10.1371/journal.pone.0068973" target="_blank" title="It opens in new window">CrossRef
14. Nawata, H, Bronzert, D, Lippman, ME (1981) Isolation and characterization of a tamoxifen-resistant cell line derived from MCF-7 human breast cancer cells. J Biol Chem. 256: pp. 5016-5021
15. Nawata, H, Chong, MT, Bronzert, D, Lippman, ME (1981) Estradiol-independent growth of a subline of MCF-7 human breast cancer cells in culture. J Biol Chem. 256: pp. 6895-6902
16. Massarweh, S, Osborne, CK, Creighton, CJ, Qin, L, Tsimelzon, A, Huang, S (2008) Tamoxifen resistance in breast tumors is driven - 刊物主题：Cancer Research; Oncology;
- 出版者：BioMed Central
- ISSN：1465-5411
文摘
Introduction The emergence of hormone therapy resistance, despite continued expression of the estrogen receptor (ER), is a major challenge to curing breast cancer. Recent clinical studies suggest that epigenetic modulation by histone deacetylase (HDAC) inhibitors reverses hormone therapy resistance. However, little is known about epigenetic modulation of the ER during acquired hormone resistance. Our recent phase II study demonstrated that HDAC inhibitors re-sensitize hormone therapy-resistant tumors to the anti-estrogen tamoxifen. In this study, we sought to understand the mechanism behind the efficacy of this combination. Methods We generated cell lines resistant to tamoxifen, named TAMRM and TAMRT, by continuous exposure of ER-positive MCF7 and T47D cells, respectively to 4-hydroxy tamoxifen for over 12?months. HDAC inhibition, along with pharmacological and genetic manipulation of key survival pathways, including ER and Bcl-2, were used to characterize these resistant models. Results The TAMRM cells displayed decreased sensitivity to tamoxifen, fulvestrant and estrogen deprivation. Consistent with previous models, ER expression was retained and the gene harbored no mutations. Compared to parental MCF7 cells, ER expression in TAMRM was elevated, while progesterone receptor (PGR) was lost. Sensitivity of ER to ligands was greatly reduced and classic ER response genes were suppressed. This model conveyed tamoxifen resistance through transcriptional upregulation of Bcl-2 and c-Myc, and downregulation of the cell cycle checkpoint protein p21, manifesting in accelerated growth and reduced cell death. Similar to TAMRM cells, the TAMRT cell line exhibited substantially decreased tamoxifen sensitivity, increased ER and Bcl-2 expression and significantly reduced PGR expression. Treatment with HDAC inhibitors reversed the altered transcriptional events and reestablished the sensitivity of the ER to tamoxifen resulting in substantial Bcl-2 downregulation, growth arrest and apoptosis. Selective inhibition of Bcl-2 mirrored these effects in presence of an HDAC inhibitor. Conclusions Our model implicates elevated ER and Bcl-2 as key drivers of anti-estrogen resistance, which can be reversed by epigenetic modulation through HDAC inhibition.